Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intranasal Therapeutics has appointed Jeff Edelson as its new executive vice president, R&D and chief medical officer.
Subscribe to our email newsletter
Previously, Jeff Edelson worked as vice president, internal medicine and therapeutic area head – Novel Therapeutics in Johnson & Johnson.
Dr Edelson prior industry experience includes leadership roles of progressive responsibility in areas of pulmonary and critical care medicine, oncology, hematology, supportive care and immunology for Johnson and Johnson, Aventis, Therion Biologics and GlaxoSmithkline.
Dr Edelson holds an MD degree and a Master of Health Sciences Administration from the University of Toronto, Canada.
Peter Young, president and CEO of Intranasal Therapeutics, said: “Jeff is a highly experienced product development and clinical research executive with an impressive track record of accomplishment. He will add enormously to ITI’s strategic reach and product development capability.”